Pharmacodynamic profile in East Asian patients with ACS treated with prasugrel standard-dose v de-escalation strategy: a randomized A-MATCH trial.

In conclusion, compared with the standard-dose prasugrel, prasugrel de-escalation strategy in East Asian patients presented with ACS showed a higher chance within the therapeutic window and a lower tendency toward bleeding episodes. PMID: 33401330 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33401330?dopt=Abstract

Source: Thrombosis and Haemostasis - January 5, 2021 Category: Hematology Authors: Jeong YH, Oh JH, Yoon HJ, Park Y, Suh J, Lee SW, Lee K, Kim JS, Chun WJ, Park YH, Nam CW, Kim JH, Ahn JH, Hwang SJ, Hwang JY, Tantry US, Gurbel P, Shin ES Tags: Thromb Haemost Source Type: research

More News: Bleeding | Hematology | Study | Thrombosis